Reverse Merger - Summary of Final Purchase Price Allocation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] $ in Thousands |
Aug. 01, 2017
USD ($)
|
|---|---|
| Business Acquisition [Line Items] | |
| Cash, cash equivalents and marketable securities | $ 12,376 |
| Prepaid expenses and other assets | 518 |
| Intangible assets license agreements | 8,610 |
| Accounts payable, accrued expenses and other liabilities | (4,054) |
| Deferred tax liability | (2,928) |
| Contingent value rights | (200) |
| Excess negative goodwill | (1,272) |
| Total purchase price | $ 13,050 |
| X | ||||||||||
- Definition Business combination bargain purchase gain as of acquisition date amount. No definition available.
|
| X | ||||||||||
- Definition Business combination recognized identifiable assets acquired and liabilities assumed cash and equivalents and marketable securities. No definition available.
|
| X | ||||||||||
- Definition Business combination recognized identifiable assets acquired and liabilities assumed contingent value rights. No definition available.
|
| X | ||||||||||
- Definition Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable accrued expenses and other liabilities. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|